Investors

IR Overview

IR Overview

IR OVERVIEW

Indu Ramachandran talks about Translational Data and what it means for patients in our trials

 

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient’s own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, second generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

 

Recent News

More >>
Date Title  
Toggle Summary Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
These next-generation SPEAR T-cells may improve long term T-cell functions PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc , Philadelphia, PA , and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE‑A4 to Enhance Antitumor Responses
These next-generation SPEAR T-cells may improve long term T-cell functions PHILADELPHIA and OXFORDSHIRE, United Kingdom , July 18, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc , Philadelphia, PA , and Oxfordshire, UK (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated
Toggle Summary Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
James Noble will transition to become a Non-Executive Director PHILADELPHIA and OXFORDSHIRE, United Kingdom , June 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe , currently Chief Financial Officer (CFO) of the Company, will succeed
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
James Noble will transition to become a Non-Executive Director PHILADELPHIA and OXFORDSHIRE, United Kingdom , June 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian Rawcliffe , currently Chief Financial Officer (CFO) of the Company, will succeed
Toggle Summary Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
- Adaptimmune to license Alpine’s Secreted and Transmembrane Immunomodulatory Protein technology for use with SPEAR T-cells to enhance antitumor responses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
- Adaptimmune to license Alpine’s Secreted and Transmembrane Immunomodulatory Protein technology for use with SPEAR T-cells to enhance antitumor responses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
Toggle Summary Adaptimmune Reports First Quarter 2019 Financial Results
- Clinical update issued in a separate announcement - - Financial guidance updated: funded into Q3 2020 - PHILADELPHIA and OXFORD, United Kingdom , May 06, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial
Adaptimmune Reports First Quarter 2019 Financial Results
- Clinical update issued in a separate announcement - - Financial guidance updated: funded into Q3 2020 - PHILADELPHIA and OXFORD, United Kingdom , May 06, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events

More >>
There are currently no events to display.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just click here.